A Study of Ravulizumab (ALXN1210) in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria
Study Identifier:
ALXN1210-PNH-304
ClinicalTrials.gov Identifier:
EudraCT Identifier:
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete
Study Details
Medical Condition
- Unmapped
Study Drug
- Biological: Ravulizumab
Date
Feb 2018 - Mar 2020
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: N/A - 17 Years
Requirements Information
Sex
Female & Male
Age
N/A - 17 Years
Study Details
Medical Condition
- Unmapped
Study Drug
- Biological: Ravulizumab
Date
Feb 2018 - Mar 2020
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: N/A - 17 Years years
Requirements Information
Protocol Summary
The purpose of this study was to assess the pharmacokinetics (PK), pharmacodynamics (PD), safety, and efficacy of ravulizumab in pediatric participants with paroxysmal nocturnal hemoglobinuria (PNH).
Trial Locations
Location
Status
Location
Clinical Trial Site
Atlanta, Georgia, United States, 30329
Status
N/A
Location
Clinical Trial Site
Milwaukee, Wisconsin, United States, 53226
Status
N/A
Location
Clinical Trial Site
Paris, France
Status
N/A
Location
Clinical Trial Site
Utrecht, Netherlands
Status
N/A
Location
Clinical Trial Site
Oslo, Norway
Status
N/A
Location
Clinical Trial Site
Moscow, Russian Federation
Status
N/A